Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.1%. By the end of trading, Regeneron Pharmaceuticals rose $2.46 (1.8%) to $136.47 on light volume. Throughout the day, 549,681 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 981,500 shares. The stock ranged in a price between $131.24-$136.70 after having opened the day at $133.34 as compared to the previous trading day's close of $134.01. Other companies within the Drugs industry that increased today were: Anika Therapeutics ( ANIK), up 28.2%, Cambrex Corporation ( CBM), up 22.1%, ProPhase Labs ( PRPH), up 16.8%, and Repligen Corporation ( RGEN), up 15.8%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $12.65 billion and is part of the health care sector. Shares are up 142.9% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins.

On the negative front, Halozyme Therapeutics ( HALO), down 49.8%, AVEO Pharmaceuticals ( AVEO), down 26.7%, K-V Pharmaceutical Company ( KV.B), down 25.4%, and Incyte ( INCY), down 21.5%, were all laggards within the drugs industry with Watson Pharmaceuticals ( WPI) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).